Alkermes plc (ALKS) Monday reported positive topline results from Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1).
The study met its primary goal showing statistically significant and clinically meaningful improvements in wakefulness compared to placebo.
Alixorexton also demonstrated robust and clinically meaningful improvements in patient-reported outcomes related to excessive daytime sleepiness and other key symptoms such as fatigue and cognition. Further, the drug candidate was generally well tolerated at all doses tested.
Alkermes said that these data support rapid initiation of a phase 3 program of alixorexton in patients with NT1.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.